Worldwide sales of drugs to treat AD approximated $4.3 billion in 2012 (Nature, 2013). The AD drug market is forecast to experience double-digit growth to 2020. The catalysts for this growth include an aging population, earlier and improved diagnosis, and the introduction of therapies that can be prescribed in addition to existing treatments (Reuter’s 2012). Industry analysts believe a single new and truly effective AD drug could capture annual sales of over $10 billion dollars. An estimated 5.2 million Americans of all ages have AD in 2013. This includes an estimated 5 million people age 65 and older and approximately 200,000 individuals younger than age 65 who have early-onset AD. The number of Americans with AD will grow as the U.S. population continues to age. By 2025, the number of people age 65 and older with AD is projected to reach 7.1 million—a 40 percent increase from the 5 million aged 65 and older that are currently affected. By 2050, the number of people with AD will nearly triple, from 5 million to a projected 13.8 million, barring the development of medical breakthroughs to prevent, slow or stop the disease.